Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Xenical (Orlistat) Helps Maximally-Medicated Diabetics Avoid Insulin: Presented at ADA

        By Bruce Sylvester
        Special to DG News

        SAN FRANCISCO, CA -- June 17, 2002 -- Orlistat (XenicalŽ) provides additional glycemic control in patients with type 2 diabetes who are not stabilized with maximal or near-maximal doses of anti-diabetes medications -- and might help them avoid going on insulin, researchers reported at annual meeting of the American Diabetes Association (ADA).

        "The findings suggest that weight loss with Xenical plus diet may provide physicians with another tool to control blood sugar in overweight or obese patients with type 2 diabetes, and prolong the utility of oral anti-diabetes medications," said lead researcher Stephan Jacob, MD, medical director of the Albert Schweitzer Klinic in Konigsfeld, Germany.

        Investigators analyzed pooled data from seven double-blind, placebo-controlled studies of orlistat treatment in overweight or obese patients with type 2 diabetes who were taking oral anti-diabetes (OAD) medications.

        Subjects had been randomized to receive either orlistat 120 mg three times per day with meals or placebo. All subjects ate a reduced calorie diet (lowered 500-600 calories per day).

        The researchers identified a subgroup of subjects who were taking maximal or near maximal doses of either metformin (2000 mg or greater) or sulfonylureas (80 percent or greater of standardized dose). After up to one year of treatment, they analyzed the data on these subjects with special regard to effects on hemoglobin A1c (HbA1c) levels and fasting plasma glucose (FPG), both indicators of glycemic control.

        In the metformin-user group, compared to the placebo-plus-diet group, orlistat-plus-diet had a greater impact on HbA1c (-0.81 percent orlistat vs.-38 percent placebo) and on FPG levels (-1.74 mmol/L orlistat vs. -0.38 mmol/L placebo). In patients treated with sulfonylureas, orlistat-plus-diet lowered HbA1c levels by -0.66 percent compared to -0.09 percent for placebo-plus-diet. Fasting plasma glucose fell by -1.24 mmol/L with orlistat versus an increase of +0.16 mmol/L with placebo.

        "In patients on maximal or near maximal doses of OADs, orlistat provides additional improvements in glycemic control," the authors concluded. "The beneficial effect of orlistat on HbA1c and FPG in patients receiving maximal or near maximal doses of metformin or sulfonylureas is similar to that seen in the overall treatment group."



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send